The role of FluoroDeoxyGlucose-Positron Emission Tomography imaging in clinical stages Ia/IIa Hodgkin's disease
ISRCTN | ISRCTN99811594 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN99811594 |
ClinicalTrials.gov number | NCT00943423 |
Secondary identifying numbers | LRF 02/20 |
- Submission date
- 20/10/2003
- Registration date
- 21/10/2003
- Last edited
- 26/10/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Contact information
Ms Bilyana Popova
Scientific
Scientific
Cancer Research UK and UCL Cancer Trials Centre
90 Tottenham Court Road
London
W1T 4TJ
United Kingdom
fdg-pet@ctc.ucl.ac.uk |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | A randomised phase III trial to determine the role of FluoroDeoxyGlucose-Positron Emission Tomography imaging in clinical stages Ia/IIa Hodgkin's disease |
Study acronym | FDG-PET |
Study objectives | Added 06/01/2009: FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) negativity after three cycles of adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) is indicative of a level of response whereby radiotherapy can be safely omitted without significantly compromising the duration of remission for patients with stage Ia/IIa Hodgkin's disease above the diaphragm. On 05/01/2009 the following changes were made to this trial record: 1. The anticipated end date was changed from 01/10/2003 to 31/12/2009 (correction) 2. The target number of participants was changed from 320 to 400. An ethics approval has been obtained for this amendment. Other changes are recorded within the relevant fields. |
Ethics approval(s) | North West Research Ethics Committee, 04/07/2003, ref: 03/8/056. An amendment to the number of participants was approved on 08/08/2008. |
Health condition(s) or problem(s) studied | Hodgkin's Disease |
Intervention | Patients with a negative PET scan after three cycles of ABVD treatment will be randomised to involved field radiotherapy or no further treatment. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase III |
Drug / device / biological / vaccine name(s) | Adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) |
Primary outcome measure | Added 05/01/2009: Three-year progression-free survival. |
Secondary outcome measures | Added 05/01/2009: 1. Incidence of FDG-PET positivity/negativity after three cycles of ABVD 2. Survival (time from date of registration/randomisation to date of death from any cause) and cause of death. Participants will be followed up until death. 3. Incidence and type of second cancers. Participants will be followed up until death. |
Overall study start date | 01/10/2003 |
Completion date | 31/12/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 400 |
Total final enrolment | 571 |
Key inclusion criteria | 1. Aged 16 - 75 years, either sex 2. Histologically confirmed Hodgkin's disease (histology will be reviewed retrospectively by Professor A Jack at the Haematological Malignancy Diagnostic Service in Leeds but please note that this is not required before trial entry) 3. Clinical stages Ia/IIa above the diaphragm with no mediastinal bulk (defined as maximum transverse diameter of mediastinal mass: internal thoracic diameter at level of D5/6 interspace greater than 0.33). Bulky disease at other sites (defined as nodal mass with transverse diameter greater than 10 cm) is acceptable. 4. No previous treatment for Hodgkin's disease 5. No previous malignancy excepting appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix 6. No contraindications to chemotherapy or radiotherapy 7. Patients with reproductive potential: a willingness to use contraception from entry into the study for a period of 6 months 8. Written informed consent |
Key exclusion criteria | 1. Patients with clinical stage Ia Hodgkin's disease with no clinical or computed tomography (CT) evidence of disease after diagnostic biopsy 2. Pregnant or lactating women 3. Severe underlying illness considered likely to make the trial therapy hazardous (for example severe heart disease or lung fibrosis) 4. Patients unwilling to travel to the nearest PET Centre 5. Patients unable to comply with follow-up arrangements |
Date of first enrolment | 01/10/2003 |
Date of final enrolment | 31/12/2009 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Cancer Research UK and UCL Cancer Trials Centre
London
W1T 4TJ
United Kingdom
W1T 4TJ
United Kingdom
Sponsor information
Leukaemia Research Fund (UK)
Charity
Charity
43 Great Ormond Street
London
WC1N 3JJ
United Kingdom
sgerscher@lrf.org.uk | |
Website | http://www.lrf.org.uk |
https://ror.org/0055acf80 |
Funders
Funder type
Charity
Leukaemia Research Fund (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | Not provided at time of registration |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 23/04/2015 | 14/02/2020 | Yes | No |
Plain English results | 26/10/2022 | No | Yes |
Editorial Notes
25/10/2022: Cancer Research UK plain English results link and total final enrolment added.
14/02/2020: ClinicalTrials.gov number and publication reference added.
20/03/2017: No publications found in PubMed, verifying study status with principal investigator.